671 Views

Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

Sunday, April 30, 2023

5:30 PM – 8:00 PM CST

Location: S100BC

Moderator(s)

Matthew R. Smith, MD, PhD

Massachusetts General Hospital/Harvard Medical School

Faculty(s)

Himisha Beltran, MD
Stephen J. Freedland, MD (he/him/his)

Cedars-Sinai Medical Center
Fred Saad, MD,FRCSC

Professor and Chief of Urology
University of Montreal
Neal D. Shore, MD (he/him/his)

Part 2 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the American Urological Association Annual Meeting 2023 (AUA2023)

To Register For This Complimentary Event, visit:
http://www.researchtopractice.com/Meetings/AUA2023

This activity is offered for in-person and virtual AUA conference attendees.

CME provided by Research To Practice

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Merck.

Location:
McCormick Place Convention Center
2301 South Martin Luther King Drive
Chicago, IL 60616

Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Dinner Meeting

This 2-hour CME-accredited in-person symposium and live webcast, part 2 of a 2-part series, will focus on the management of patients with prostate cancer. Research To Practice (RTP) will recruit five clinical investigators with an expertise and/or specialized interest in the management of prostate
cancer to serve as the faculty, one of whom will moderate the program.

To support the theme of the project, in the first quarter of 2023 RTP will recruit 17 US-based and international urologic oncology clinical investigators who, in addition to the invited faculty members, will participate in a unique educational assessment. As part of the assessment, each investigator will be asked to complete a survey consisting of approximately 50 case-based and related management questions intended to illuminate their general practice patterns related to the treatment of patients with prostate cancer. At the conclusion of the assessment, RTP will aggregate and analyze all of the investigator-provided information in order to prioritize key topics and identify interesting data points and patient care issues for inclusion in the live event. For each data point selected for inclusion, a custom-designed slide will be created to anonymously illustrate the preferred treatment or related response from each faculty member and the other 17 surveyed investigators.

During the live meeting, in person clinician attendees will be provided networked iPads to participate in interactive polling which will include a number of the same questions posed as part of the premeeting investigator survey. Virtual attendees will be able to complete the same survey on our Zoom platform. Throughout the symposium, results of the interactive audience polling will be juxtaposed with the findings from the investigator survey to observe educational gaps and establish a framework for discussion. Each faculty member will also be asked to prepare and deliver an approximately 10-minute presentation focused on reviewing recently published research data and ongoing clinical trials related to the topics and questions addressed via the survey. Following each of the faculty presentations, moderated panel discussion and the introduction of additional findings and trends observed from the investigator assessment will ensue to generate other relevant perspectives and dialogue. Clinicians will also be encouraged to use the iPads throughout the event to submit additional questions. The moderator will incorporate a number of these queries into the panel discussions in order to stimulate additional debate.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A CME credit link will be given to each participant at the conclusion of the activity.

Learning Objectives:

Appraise published research findings and current guideline recommendations on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and appropriately counsel patients about the potential benefits of systemic therapy.
Evaluate the research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in presenting nonresearch treatment options to patients.
Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
Establish an evidence-based approach to the selection and sequencing of therapies for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
Assess the research database supporting the use of PARP inhibitors as monotherapy for patients with mCRPC harboring a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
Develop an understanding of the rationale for, available and emerging data with and ongoing research evaluating PARP inhibitors in combination with androgen receptor-targeted therapy, and consider the potential role of these novel regimens in therapy for patients both with and without HRR gene mutations.
Appreciate Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the current clinical role of this strategy.
Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.